目的:检测TLR3、NF-κB及IL-1β在宫颈上皮内瘤变( CIN)与宫颈癌中的表达,探讨3者的相关性及其与临床病理参数的关系。方法:收集中国医科大学附属盛京医院2014年1月至2014年12月妇科手术标本共120例,其中宫颈鳞癌60例, CIN 40例,正常宫颈20例。采用免疫组化法检测TLR3、NF-κB及IL-1β表达。结果:正常宫颈、CIN、宫颈癌中TLR3阳性表达率分别为100%、75%、23.23%,NF-κB阳性表达率为0%、60%、90%, IL-1β阳性表达率为0%、70%、90%,各组间差异均有统计学意义( P〈0.005)。 TLR3表达与宫颈癌临床分期相关(P〈0.05);NF-κB及IL-1β与临床分期、病理分级及淋巴结转移相关(P〈0.05)。 TLR3与 NF-κB、IL-1β表达均呈显著负相关(rs=-0.478,P〈0.01;rs=-0.45,P〈0.01);NF-κB与IL-1β表达呈显著正相关( rs=0.589,P〈0.01)。结论:宫颈癌中TLR3呈低表达,NF-κB与IL-1β均呈高表达,可为TLR激动剂治疗宫颈癌提供一定的理论依据。
Objective:To detect the expression of TLR3,NF-κB and IL-1β in the cer-vical intraepithelial neoplasia(CIN) and cervical squamous cell carcinoma,to investigate the relationship among them and the relationship with clinicopathological parameters. Methods:120 cases of gynecologic surgery specimen were collected in Shengjing Hospital of China Medical U-niversity between Jan. 2014 and Dec. 2014,including 60 cases of cervical squamous cell carci-noma,40 cases of CIN and 20 cases of normal cervical tissue. The expression of TLR3,NF-κB and IL-1β was detected using immunohistochemical methods. Results:The positive expression rates of TLR3 were 100%,75%,23. 23% respectively in normal cervix, CIN, and cervical squamous cell carcinoma. The positive expression rates of NF-κB and IL-1β were 0%,60%, 90% and 0%,70%,90%. The differences among these groups were statistically significant( P〈0 . 005 ) . The expression of TLR3 was associated with clinical stage in cervical squamous cell carcinoma(P〈0. 05). The expression of NF-κB and IL-1β was associated with clinical stage, pathological grading and lymph node metastasis(P〈0. 05). There was no significant relationship between the expression and patients'age (P〉0. 05). There was significantly negative correlation between the expression of TLR3 and NF-κB, IL-1β( rs=-0. 478, P〈0. 01;rs=-0. 45, P〈0. 01). There was significantly positive correlation between NF-κB and IL-1β(rs=0. 589,P〈0. 01). Conclusion:The expression of TLR3 decreased in cervical cancer,while the expression of NF-κB and IL-1βincreased. It could provide certain theory basis for the TLR agonists to treat cervical cancer.